E. Özkan, Burak Demir, Diğdem Kuru Öz, Y. Ürün, N. O. Küçük
{"title":"一例通过 18F-FDG PET/MRI 证实对索拉非尼治疗有明显反应的弥漫浸润性肝细胞癌病例","authors":"E. Özkan, Burak Demir, Diğdem Kuru Öz, Y. Ürün, N. O. Küçük","doi":"10.4274/mirt.galenos.2024.36043","DOIUrl":null,"url":null,"abstract":"A 73-year-old woman with known diagnosis of chronic hepatitis B infection referred for 18 F-fluorodeoxyglucose positron emission tomography/ computed tomography ( 18 F-FDG PET/CT) and magnetic resonance imaging (MRI) after detection of a liver mass with 9 cm diameter in contrast enhanced CT. However, 18 F-FDG PET/CT and MRI revealed diffuse infiltrating hepatocellular carcinoma lesions other than previously defined mass. After 9 months of Sorafenib treatment serum alpha feto protein levels dropped from 60,500 ng/mL to 801 ng/mL. Later 18 F-FDG PET/MRI was performed for evaluation of response to treatment and revealed marked response to treatment","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Case of Diffuse Infiltrative Hepatocellular Carcinoma with Marked Response to Sorafenib Treatment Evidenced by 18F-FDG PET/MRI\",\"authors\":\"E. Özkan, Burak Demir, Diğdem Kuru Öz, Y. Ürün, N. O. Küçük\",\"doi\":\"10.4274/mirt.galenos.2024.36043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A 73-year-old woman with known diagnosis of chronic hepatitis B infection referred for 18 F-fluorodeoxyglucose positron emission tomography/ computed tomography ( 18 F-FDG PET/CT) and magnetic resonance imaging (MRI) after detection of a liver mass with 9 cm diameter in contrast enhanced CT. However, 18 F-FDG PET/CT and MRI revealed diffuse infiltrating hepatocellular carcinoma lesions other than previously defined mass. After 9 months of Sorafenib treatment serum alpha feto protein levels dropped from 60,500 ng/mL to 801 ng/mL. Later 18 F-FDG PET/MRI was performed for evaluation of response to treatment and revealed marked response to treatment\",\"PeriodicalId\":44681,\"journal\":{\"name\":\"Molecular Imaging and Radionuclide Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Imaging and Radionuclide Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/mirt.galenos.2024.36043\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2024.36043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
A Case of Diffuse Infiltrative Hepatocellular Carcinoma with Marked Response to Sorafenib Treatment Evidenced by 18F-FDG PET/MRI
A 73-year-old woman with known diagnosis of chronic hepatitis B infection referred for 18 F-fluorodeoxyglucose positron emission tomography/ computed tomography ( 18 F-FDG PET/CT) and magnetic resonance imaging (MRI) after detection of a liver mass with 9 cm diameter in contrast enhanced CT. However, 18 F-FDG PET/CT and MRI revealed diffuse infiltrating hepatocellular carcinoma lesions other than previously defined mass. After 9 months of Sorafenib treatment serum alpha feto protein levels dropped from 60,500 ng/mL to 801 ng/mL. Later 18 F-FDG PET/MRI was performed for evaluation of response to treatment and revealed marked response to treatment
期刊介绍：
Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
